ICD-10-PCS › X New Technology › XW Anatomical Regions › XW0 New Technology, Anatomical... › XW097M5
XW097M5
Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5
RetiredICD-10-PCS procedure code.
No longer in the code set. Submitting it will not be accepted for a current date of service.
Use instead:
- 3E097GC Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening stated for FY2024
What has happened to this code
Every change the publisher made, from 2021 to now.
- FY2021 Added to the code set Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5
- FY2025 Removed from the code set
What this code says
Each character is read in its own position, so the same letter means different things in different places. Definitions are CMS's own.
3. Root operation Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
5. Approach Via Natural or Artificial Opening
Entry of instrumentation through a natural or artificial external opening to reach the site of the procedure
6. Device / Substance / Technology Brexucabtagene Autoleucel Immunotherapy
For example
- Brexucabtagene Autoleucel
- Tecartus(tm)
Codes in the same group
| Code | Description | Status |
|---|---|---|
| XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 | Retired |
| XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW01329 | Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |
| XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0134C | Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 | Valid |
| XW0136A | Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 | Valid |
| XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | Retired |
| XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | Valid |
| XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |